Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

2.
3.

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.

Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE, Williams RM.

Cancer Chemother Pharmacol. 2015 Apr;75(4):671-82. doi: 10.1007/s00280-015-2675-1. Epub 2015 Jan 24.

PMID:
25616967
4.

Veterinary oncology clinical trials: Design and implementation.

Thamm DH, Vail DM.

Vet J. 2014 Dec 19. pii: S1090-0233(14)00509-7. doi: 10.1016/j.tvjl.2014.12.013. [Epub ahead of print]

PMID:
25582798
5.

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.

Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH.

J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429.

PMID:
25274443
6.

The immunosignature of canine lymphoma: characterization and diagnostic application.

Johnston SA, Thamm DH, Legutki JB.

BMC Cancer. 2014 Sep 8;14:657. doi: 10.1186/1471-2407-14-657.

7.

Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis.

Weishaar KM, Thamm DH, Worley DR, Kamstock DA.

J Comp Pathol. 2014 Nov;151(4):329-38. doi: 10.1016/j.jcpa.2014.07.004. Epub 2014 Aug 27.

PMID:
25172053
8.

Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog.

Weishaar KM, Edmondson EF, Thamm DH, Olver CS.

Vet Clin Pathol. 2014 Sep;43(3):447-52. doi: 10.1111/vcp.12180. Epub 2014 Jul 30.

PMID:
25132008
9.

Serum 25-hydroxyvitamin D concentrations in dogs - correlation with health and cancer risk.

Selting KA, Sharp CR, Ringold R, Thamm DH, Backus R.

Vet Comp Oncol. 2014 Jul 8. doi: 10.1111/vco.12101. [Epub ahead of print]

PMID:
25041357
10.

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH.

Autophagy. 2014 Aug;10(8):1415-25. doi: 10.4161/auto.29165. Epub 2014 May 20.

PMID:
24991836
11.

Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.

Shoeneman JK, Ehrhart EJ 3rd, Charles JB, Thamm DH.

Vet Comp Oncol. 2014 Jun 13. doi: 10.1111/vco.12104. [Epub ahead of print]

PMID:
24923332
12.

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH.

BMC Vet Res. 2014 May 6;10:105. doi: 10.1186/1746-6148-10-105.

13.

Autophagy and cancer therapy.

Thorburn A, Thamm DH, Gustafson DL.

Mol Pharmacol. 2014 Jun;85(6):830-8. doi: 10.1124/mol.114.091850. Epub 2014 Feb 26. Review.

PMID:
24574520
14.

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE.

J Vet Intern Med. 2014 Mar-Apr;28(2):554-63. doi: 10.1111/jvim.12313. Epub 2014 Feb 10.

PMID:
24512451
15.

GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Thamm DH, Vail DM, Kurzman ID, Babusis D, Ray AS, Sousa-Powers N, Tumas DB.

BMC Vet Res. 2014 Jan 25;10:30. doi: 10.1186/1746-6148-10-30.

16.

Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.

Kaye ME, Thamm DH, Weishaar K, Lawrence JA.

Vet Comp Oncol. 2013 Aug 25. doi: 10.1111/vco.12065. [Epub ahead of print]

PMID:
23981116
17.

DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study.

Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM.

PLoS One. 2013 Jul 23;8(7):e69192. doi: 10.1371/journal.pone.0069192. Print 2013.

18.

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.

Dailey DD, Anfinsen KP, Pfaff LE, Ehrhart EJ, Charles JB, Bønsdorff TB, Thamm DH, Powers BE, Jonasdottir TJ, Duval DL.

BMC Vet Res. 2013 Jul 1;9:130. doi: 10.1186/1746-6148-9-130.

19.

Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.

Lawrence JA, Huelsmeyer MK, Thamm DH, Tumas DB, Birkus G, Kurzman I, Vail DM.

Vet Comp Oncol. 2013 May 15. doi: 10.1111/vco.12038. [Epub ahead of print]

20.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Nguyen SM, Thamm DH, Vail DM, London CA.

Vet Comp Oncol. 2013 Mar 28. doi: 10.1111/vco.12032. [Epub ahead of print]

PMID:
23534501
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk